Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Incretins | 3 | 2021 | 61 | 2.36 | Why? |
| Glucagon-Like Peptide-1 Receptor | 5 | 2021 | 138 | 1.86 | Why? |
| Hypoglycemic Agents | 12 | 2021 | 2165 | 1.30 | Why? |
| Diabetes Mellitus, Type 2 | 8 | 2021 | 6166 | 1.00 | Why? |
| Liraglutide | 2 | 2019 | 47 | 0.94 | Why? |
| Atherosclerosis | 3 | 2019 | 768 | 0.90 | Why? |
| Dyslipidemias | 4 | 2019 | 791 | 0.71 | Why? |
| Periodontitis | 1 | 2018 | 171 | 0.63 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2020 | 436 | 0.60 | Why? |
| Lipoproteins, LDL | 3 | 2018 | 115 | 0.60 | Why? |
| Dietary Supplements | 7 | 2019 | 2251 | 0.59 | Why? |
| Metabolic Syndrome | 3 | 2018 | 810 | 0.58 | Why? |
| Cholesterol, LDL | 2 | 2018 | 499 | 0.54 | Why? |
| Plaque, Atherosclerotic | 1 | 2018 | 423 | 0.52 | Why? |
| Lipids | 5 | 2019 | 1079 | 0.46 | Why? |
| Cardiovascular Diseases | 11 | 2019 | 11497 | 0.45 | Why? |
| Diabetes Mellitus | 4 | 2021 | 8207 | 0.45 | Why? |
| Diabetes Complications | 3 | 2020 | 2358 | 0.44 | Why? |
| Hypolipidemic Agents | 4 | 2019 | 208 | 0.41 | Why? |
| Lipoproteins, HDL | 2 | 2009 | 154 | 0.35 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 1510 | 0.33 | Why? |
| Schistosoma | 1 | 2005 | 6 | 0.32 | Why? |
| Diabetes Mellitus, Type 1 | 2 | 2019 | 1969 | 0.31 | Why? |
| Schistosomiasis mansoni | 1 | 2005 | 35 | 0.31 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.25 | Why? |
| Blood Glucose | 5 | 2020 | 3642 | 0.24 | Why? |
| Silymarin | 2 | 2019 | 17 | 0.24 | Why? |
| Lipoprotein(a) | 2 | 2017 | 92 | 0.22 | Why? |
| Coronary Artery Disease | 2 | 2019 | 2570 | 0.20 | Why? |
| Dosage Forms | 1 | 2018 | 11 | 0.20 | Why? |
| Pregnancy in Diabetics | 1 | 2019 | 56 | 0.18 | Why? |
| Glucagon-Like Peptides | 1 | 2018 | 29 | 0.18 | Why? |
| Glucagon-Like Peptide 1 | 1 | 2018 | 83 | 0.18 | Why? |
| Pistacia | 1 | 2017 | 5 | 0.18 | Why? |
| Euphausiacea | 1 | 2017 | 3 | 0.18 | Why? |
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 907 | 0.18 | Why? |
| Berberine | 1 | 2019 | 98 | 0.18 | Why? |
| Dietary Fats, Unsaturated | 1 | 2017 | 14 | 0.18 | Why? |
| Benzo(a)pyrene | 1 | 2017 | 4 | 0.18 | Why? |
| Heme Oxygenase-1 | 2 | 2016 | 90 | 0.18 | Why? |
| Carotid Intima-Media Thickness | 1 | 2019 | 179 | 0.17 | Why? |
| Intestinal Mucosa | 1 | 2005 | 1046 | 0.17 | Why? |
| Brachial Artery | 1 | 2017 | 107 | 0.17 | Why? |
| Tamoxifen | 1 | 2017 | 83 | 0.16 | Why? |
| Lipid Metabolism | 2 | 2017 | 572 | 0.15 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.15 | Why? |
| Vasodilation | 1 | 2017 | 258 | 0.15 | Why? |
| Angina, Stable | 1 | 2015 | 45 | 0.14 | Why? |
| Anticholesteremic Agents | 1 | 2017 | 186 | 0.14 | Why? |
| DNA Damage | 1 | 2017 | 285 | 0.14 | Why? |
| Diet | 2 | 2017 | 2052 | 0.14 | Why? |
| Disease Notification | 1 | 2020 | 639 | 0.14 | Why? |
| Humans | 45 | 2021 | 930598 | 0.14 | Why? |
| Polyphenols | 1 | 2018 | 283 | 0.13 | Why? |
| Diabetes, Gestational | 1 | 2018 | 426 | 0.12 | Why? |
| Overweight | 1 | 2019 | 916 | 0.12 | Why? |
| Particle Size | 1 | 2017 | 1052 | 0.12 | Why? |
| Bilirubin | 1 | 2015 | 503 | 0.12 | Why? |
| Patient Preference | 1 | 2018 | 750 | 0.11 | Why? |
| DNA | 1 | 2017 | 778 | 0.11 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.11 | Why? |
| Coronary Disease | 1 | 2017 | 645 | 0.11 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.11 | Why? |
| Cholesterol, HDL | 1 | 2013 | 439 | 0.10 | Why? |
| Peripheral Arterial Disease | 1 | 2016 | 471 | 0.10 | Why? |
| Bronchi | 1 | 2017 | 1048 | 0.10 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.10 | Why? |
| Sleep Apnea, Obstructive | 1 | 2018 | 668 | 0.10 | Why? |
| Proteins | 1 | 2017 | 921 | 0.09 | Why? |
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 238 | 0.09 | Why? |
| Inflammation Mediators | 1 | 2020 | 2654 | 0.09 | Why? |
| Lipoproteins | 1 | 2010 | 240 | 0.09 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.09 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 1261 | 0.09 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.08 | Why? |
| Signal Transduction | 2 | 2021 | 7207 | 0.08 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.08 | Why? |
| Pregnancy Complications | 1 | 2018 | 1388 | 0.08 | Why? |
| Parasite Egg Count | 1 | 2005 | 14 | 0.08 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.08 | Why? |
| Gemfibrozil | 1 | 2005 | 2 | 0.08 | Why? |
| Hyperlipoproteinemias | 1 | 2005 | 7 | 0.08 | Why? |
| Praziquantel | 1 | 2005 | 44 | 0.08 | Why? |
| Postprandial Period | 1 | 2005 | 45 | 0.08 | Why? |
| Oxidative Stress | 1 | 2016 | 2050 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2019 | 2107 | 0.07 | Why? |
| Anthelmintics | 1 | 2005 | 104 | 0.07 | Why? |
| Psoriasis | 1 | 2019 | 1739 | 0.07 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.07 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.07 | Why? |
| Apolipoproteins | 1 | 2003 | 33 | 0.06 | Why? |
| MicroRNAs | 1 | 2016 | 1787 | 0.06 | Why? |
| Insulin | 3 | 2019 | 1316 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Animals | 6 | 2021 | 78931 | 0.06 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.06 | Why? |
| Heterozygote | 1 | 2003 | 249 | 0.06 | Why? |
| Randomized Controlled Trials as Topic | 5 | 2019 | 10649 | 0.06 | Why? |
| Female | 16 | 2020 | 380317 | 0.06 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Biomarkers | 4 | 2017 | 23361 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Double-Blind Method | 3 | 2019 | 5988 | 0.05 | Why? |
| Insulin Resistance | 2 | 2019 | 669 | 0.05 | Why? |
| Asthma | 1 | 2018 | 4383 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Drug Administration Routes | 1 | 2018 | 106 | 0.05 | Why? |
| Italy | 2 | 2020 | 38444 | 0.05 | Why? |
| Romania | 1 | 2020 | 590 | 0.04 | Why? |
| Commiphora | 1 | 2017 | 2 | 0.04 | Why? |
| Angiotensinogen | 1 | 2017 | 7 | 0.04 | Why? |
| Chlorogenic Acid | 1 | 2017 | 25 | 0.04 | Why? |
| Plant Gums | 1 | 2017 | 6 | 0.04 | Why? |
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2017 | 26 | 0.04 | Why? |
| MEDLINE | 1 | 2017 | 76 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2018 | 118 | 0.04 | Why? |
| Inulin | 1 | 2017 | 51 | 0.04 | Why? |
| Male | 13 | 2020 | 367725 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| Selective Estrogen Receptor Modulators | 1 | 2017 | 65 | 0.04 | Why? |
| Fatty Acid-Binding Proteins | 1 | 2017 | 93 | 0.04 | Why? |
| Anthropometry | 1 | 2018 | 233 | 0.04 | Why? |
| Diabetic Cardiomyopathies | 1 | 2018 | 79 | 0.04 | Why? |
| Lipid Peroxides | 1 | 2016 | 8 | 0.04 | Why? |
| Isoprostanes | 1 | 2016 | 22 | 0.04 | Why? |
| Blood Flow Velocity | 1 | 2017 | 193 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Polysomnography | 1 | 2018 | 296 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Vital Capacity | 1 | 2018 | 399 | 0.04 | Why? |
| Publication Bias | 1 | 2017 | 241 | 0.04 | Why? |
| Diet, High-Fat | 1 | 2017 | 161 | 0.04 | Why? |
| Blood Pressure | 2 | 2018 | 2198 | 0.04 | Why? |
| Diabetic Angiopathies | 1 | 2018 | 146 | 0.04 | Why? |
| Mitochondrial Proteins | 1 | 2017 | 152 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.04 | Why? |
| Middle Aged | 10 | 2020 | 270681 | 0.04 | Why? |
| Obesity | 2 | 2020 | 7388 | 0.04 | Why? |
| Forced Expiratory Volume | 1 | 2018 | 632 | 0.04 | Why? |
| Triglycerides | 2 | 2010 | 478 | 0.04 | Why? |
| Choice Behavior | 1 | 2018 | 319 | 0.04 | Why? |
| Glutathione | 1 | 2016 | 280 | 0.03 | Why? |
| Hypoglycemia | 1 | 2019 | 406 | 0.03 | Why? |
| United States | 1 | 2021 | 46150 | 0.03 | Why? |
| Statistics as Topic | 1 | 2016 | 370 | 0.03 | Why? |
| Prospective Studies | 1 | 2019 | 43301 | 0.03 | Why? |
| Fasting | 1 | 2019 | 555 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Weight Loss | 1 | 2018 | 826 | 0.03 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.03 | Why? |
| Feces | 1 | 2005 | 4235 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.03 | Why? |
| RNA, Messenger | 2 | 2017 | 5131 | 0.03 | Why? |
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 436 | 0.03 | Why? |
| Curcumin | 1 | 2017 | 396 | 0.03 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.03 | Why? |
| Angiotensin II | 1 | 2017 | 601 | 0.03 | Why? |
| Therapies, Investigational | 1 | 2013 | 235 | 0.03 | Why? |
| Proteolysis | 1 | 2015 | 751 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Dietary Proteins | 1 | 2010 | 112 | 0.02 | Why? |
| Aged | 8 | 2020 | 215776 | 0.02 | Why? |
| Genetic Therapy | 1 | 2013 | 409 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.02 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.02 | Why? |
| Vitamins | 1 | 2018 | 1208 | 0.02 | Why? |
| Cesarean Section | 1 | 2019 | 2089 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.02 | Why? |
| Motor Activity | 1 | 2010 | 217 | 0.02 | Why? |
| Statistics, Nonparametric | 1 | 2010 | 1008 | 0.02 | Why? |
| Lipoproteins, VLDL | 1 | 2005 | 8 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Endothelium, Vascular | 1 | 2017 | 1751 | 0.02 | Why? |
| Body Composition | 1 | 2010 | 414 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Plant Extracts | 1 | 2017 | 1514 | 0.02 | Why? |
| Up-Regulation | 1 | 2013 | 2249 | 0.02 | Why? |
| Pilot Projects | 1 | 2016 | 5182 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Apoprotein(a) | 1 | 2003 | 1 | 0.02 | Why? |
| Adult | 6 | 2018 | 244371 | 0.02 | Why? |
| Regression Analysis | 1 | 2010 | 2484 | 0.01 | Why? |
| Protein Isoforms | 1 | 2003 | 347 | 0.01 | Why? |
| South Africa | 1 | 2010 | 3326 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.01 | Why? |
| Patient Selection | 1 | 2010 | 4560 | 0.01 | Why? |
| Immunoassay | 1 | 2010 | 4485 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2010 | 8495 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
Rizzo's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(50)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_